SCHEMBL29644944

SCHEMBL29644944

Oc1c2cccc1Cc1cccc(c1O)Cc1cccc(c1O)Cc1cccc(c1O)Cc1cccc(c1O)Cc1cccc(c1O)Cc1cccc(c1O)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.48
▸ CYP3A4 P08684 3/20 0.48
▸ HSD17B10 Q99714 3/20 0.48
▸ TSHR P16473 2/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ USP2 O75604 1/20 0.48
▸ HPN P05981 1/20 0.48
▸ ALOX5 P09917 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ PTGS1 P23219 1/20 0.48
▸ PDE4A P27815 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ SIRT5 Q9NXA8 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.48
▸ CA2 P00918 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471552 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL12168748 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29383145 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL2471777 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29469562 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL29366399 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL19113839 0.91 TSHR (0.43) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL13821762 0.87 ALDH1A1 (0.42) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL14507604 0.87 CYP3A4 (0.40) ALDH1A1CYP3A4HSD17B10TSHRALOX15
SCHEMBL13894504 0.87 ALDH1A1 (0.40) ALDH1A1CYP3A4HSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117046514-A Catalyst for liquid-phase Beckmann rearrangement as well as preparation method and application thereof 北京旭阳科技有限公司 2023-11-14 — — CN claimed
US-12623942-B2 Method for extracting salts and temperature- regenerated extracting composition ADIONICS (FR) 2026-05-12 — — US disclosed
CN-120004431-A Oxygen carrying material for oxygenation treatment of water body, and preparation method and application thereof 中国建筑第八工程局有限公司 2025-05-16 — — CN disclosed
US-12049440-B2 Processes for preparing calixarenes SI GROUP, INC. (US) 2024-07-30 — — US disclosed
CN-117046514-A Catalyst for liquid-phase Beckmann rearrangement as well as preparation method and application thereof 北京旭阳科技有限公司 2023-11-14 — — CN disclosed
US-11772997-B2 Method for extracting salts and temperature-regenerated extracting composition ADIONICS (FR) 2023-10-03 — — US disclosed
US-20220177397-A1 PROCESSES FOR PREPARING CALIXARENES SI GROUP, INC. 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177397-A1 PROCESSES FOR PREPARING CALIXARENES CALU, CALD1, CALR ALDH1A1 254/4885CYP3A4 262/4885HSD17B10 1713/4885
US-12623942-B2 Method for extracting salts and temperature- regenerated extracting composition POLQ, NONO, AQP3 ALDH1A1 3793/4885CYP3A4 2000/4885HSD17B10 3726/4885
US-12049440-B2 Processes for preparing calixarenes CALU, CALD1, CALR ALDH1A1 254/4885CYP3A4 262/4885HSD17B10 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback